熱門資訊> 正文

分子蛋白生物技术报告财年业绩

2026-03-20 02:59

Moleculin Biotech, Inc.(MBRX) 0

Moleculin Biotech press release (MBRX): FY EPS of -$28.42.
As of December 31, 2025, the Company had cash and cash equivalents of $8.9 million and prepaid expenses and other current assets of $0.8 million.

More on Moleculin Biotech

Moleculin Biotech secures $8.3M from warrant exercises, issues new 5-year warrants
Seeking Alpha’s Quant Rating on Moleculin Biotech
Historical earnings data for Moleculin Biotech
Financial information for Moleculin Biotech

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。